Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.

Clinical lung cancer - 1 Jan 2017

Jakubowski Christopher D, Plodkowski Andrew J, Chang Jason C, Rekhtman Natasha, Iqbal Afsheen, Paik Paul K, Yu Helena A

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Drug-Related Side Effects and Adverse Reactions
Share to Erlotinib Hydrochloride

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, erbB-1

Share to Lung Diseases, Interstitial

Share to Quinazolines

Share to Remission Induction

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 27863924
DOI: 10.1016/j.cllc.2016.10.001
PMCID: PMC5490243

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.PMID 27863924Read ↗

Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer.Semantic proximity Read ↗

Successful Afatinib Therapy after Resistance to EGFR-TKI in a Patient with Advanced Adenosquamous Cell Lung Cancer.Semantic proximity Read ↗

Complete Remission to Afatinib in a Patient Harboring a Novel Epidermal Growth Factor Mutation in De Novo Small-Cell Lung Cancer: A Case Report: Clinical Lung Cancer.Semantic proximity Read ↗

Efficacy of Osimertinib in Afatinib-resistant Lung Cancer Harboring Uncommon EGFR Mutations: Case Report and Literature Review.Semantic proximity Read ↗

Osimertinib-Induced Lung Injury and Treatment Rechallenge: Clinical Insights From a Case Report With a Comprehensive Literature Review.Semantic proximity Read ↗

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib.Semantic proximity Read ↗

Successful administration of low-dose almonertinib in a patient with lung adenocarcinoma after osimertinib-induced interstitial lung disease: a case report and literature review.Semantic proximity Read ↗

Case sharing of a patient re-challenged with afatinib for EGFR-mutated advanced non-small cell lung cancer.Semantic proximity Read ↗

Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations.Semantic proximity Read ↗

Afatinib for lung cancer: let there be light?Semantic proximity Read ↗

Interstitial pneumonitis associated with EGFR/ ALK tyrosine kinase inhibitors used in non-small cell lung cancer: an observational, retrospective, pharmacovigilance study.Semantic proximity Read ↗

Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.